Maryam Dehghani - Department Of Biostatistics Shahid Beheshti University Of Medical Sciences, Tehran, Iran
Ahmadreza Baghestani - Department Of Biostatistics Shahid Beheshti University Of Medical Sciences, Tehran, Iran
Mahdi Allahbakhshian - Department Of Hematology Shahid Beheshti University Of Medical Sciences, Tehran, Iran
Somayeh Yazdani - Department Of Biostatistics Shahid Beheshti University Of Medical Sciences, Tehran, Iran

Hematologic cancers of cancers of the blood, bone marrow and lymph nodes that include leukemia,lymphoma and myeloma. A bone marrow transplant (stem cell transplant) is a treatment for hematologic cancer. Determining the survival rate of patients with hematologic cancer after bone marrow transplant is important. The aim of this study was to Comparison of the healing model and the Weibull model in the data of patients with leukemia receiving bone marrow transplantation.In a retrospective study, total of 477 patients 2 to 67 years with hematologic cancer who had received bone marrow transplant research center(2007-2016), Taleghani hospital, Tehran, Iran entered to this study. The result indicated that, the mean survival time was 2418 days with a standard error 71 days. The confidence interval %95 for mean survival time was(2287 , 2558 ). Variables age, sex, type of disease, relapses prior to transplantation and type of Bone Marrow Transplant(BMT). The final variable is the time of diagnosis to death.We found that there was a cure ratio among cancer patients who had bone marrow transplants. The AIC showed the cure model provide better fit

Breast Cancer, Blood Cancer, Cancer Stem Cells, Stem Cells and Cancer, Cancer Treatment and Management